This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

J. Craig Nelson, MD; Carolyn M. Mazure, PhD; Malcolm B. Bowers, Jr, MD; Peter I. Jatlow, MD

Arch Gen Psychiatry. 1991;48(4):303-307.

Abstract
• Prompted by a recent study suggesting that the combination of desipramine hydrochloride and fluoxetine down-regulates β-adrenergic receptors more rapidly than either drug alone, we administered both desipramine and fluoxetine to 14 inpatients with major depression in an open, 4-week trial. Desipramine plasma levels drawn 24 hours after an initial standardized dose were used to rapidly adjust desipramine dosage and compensate for the interactive effects of fluoxetine on desipramine levels in the blood. Responses were retrospectively compared with those of 52 inpatients who were descriptively similar and previously treated in the same setting with desipramine alone. Response was significantly more rapid in the group that received both drugs. One week after treatment began, the mean change in Hamilton Depression Rating Scale scores was 42% in the group that received both drugs and 20% in the group that received desipramine alone (Mann-Whitney U Test, P =.007). Two weeks after administration of the drugs, the mean change in scores of the group that received both drugs was 60%, while a 30% change was noted in the patients treated with desipramine alone (P=.001). Ten (71%) of the 14 patients in the group that received both drugs completely remitted (change in Hamilton Depression Rating Scale score of >75%, and final score of <7) within 4 weeks, while few patients treated with desipramine alone met these criteria within 4 weeks. This preliminary study suggests that treatment with both desipramine and fluoxetine is a rapid and effective strategy for treatment of major depression, and supports recent hypotheses of noradrenergic-serotonergic synergism.

Author Affiliations
From the Department of Psychiatry, Yale University School of Medicine, New Haven, Conn.

Footnotes
Accepted for publication November 19, 1990.

Presented as a poster exhibit at the American Psychiatric Association Annual Meeting, New York, NY, May 16, 1990.

Reprint requests to 20 York St, New Haven, CT, 06504 (Dr Nelson).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Authors' reply
Palaniyappan et al.
Adv. Psychiatr. Treat. 2010;16:78-80.
FULL TEXT  

Efficacy of venlafaxine compared with tricyclic antidepressants in depressive disorder: a meta-analysis
van den Broek et al.
J Psychopharmacol 2009;23:708-713.
ABSTRACT  

Duloxetine: A balanced and selective norepinephrine- and serotonin-reuptake inhibitor
Westanmo et al.
Am J Health Syst Pharm 2005;62:2481-2490.
ABSTRACT | FULL TEXT  

Duloxetine for the Treatment of Major Depressive Disorder in Women Ages 40 to 55 Years
Burt et al.
Psychosomatics 2005;46:345-354.
ABSTRACT | FULL TEXT  

Maternal Fluoxetine Treatment in the Postpartum Period: Effects on Platelet Serotonin and Plasma Drug Levels in Breastfeeding Mother-Infant Pairs
Epperson et al.
Pediatrics 2003;112:e425-425.
ABSTRACT | FULL TEXT  

Treatment and Prevention of Depression
Hollon et al.
Psychological Science in the Public Interest 2002;3:39-77.
ABSTRACT  

Inhibition of Norepinephrine Uptake in Patients With Major Depression Treated With Paroxetine
Gilmor et al.
Am. J. Psychiatry 2002;159:1702-1710.
ABSTRACT | FULL TEXT  

Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study
Beyer et al.
J Psychopharmacol 2002;16:297-304.
ABSTRACT  

Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis
SMITH et al.
Br. J. Psychiatry 2002;180:396-404.
ABSTRACT | FULL TEXT  

Strategies for Treatment Refractory Depression
Goren
Journal of Pharmacy Practice 2001;14:478-487.
ABSTRACT  

Can Recovery From Depression Be Achieved?
Shelton and Tomarken
Psychiatr. Serv. 2001;52:1469-1478.
ABSTRACT | FULL TEXT  

Critical Use of Venlafaxine Serology to Uncover Genetic Rapid Metabolism
SCHALLER and BEHAR
J. Neuropsychiatry Clin. Neurosi. 2001;13 :112-113.
FULL TEXT  

Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs: Meta-regression analysis
FREEMANTLE et al.
Br. J. Psychiatry 2000;177:292-302.
ABSTRACT | FULL TEXT  

Timing of Onset of Antidepressant Response With Fluoxetine Treatment
Nierenberg et al.
Am. J. Psychiatry 2000;157:1423-1428.
ABSTRACT | FULL TEXT  

Evidence of the Dual Mechanisms of Action of Venlafaxine
Harvey et al.
Arch Gen Psychiatry 2000;57:503-509.
ABSTRACT | FULL TEXT  

In Vivo Chronoamperometric Measures of Extracellular Serotonin Clearance in Rat Dorsal Hippocampus: Contribution of Serotonin and Norepinephrine Transporters
Daws et al.
J. Pharmacol. Exp. Ther. 1998;286:967-976.
ABSTRACT | FULL TEXT  

Electrophysiological Characterization of the Effect of Long-Term Duloxetine Administration on the Rat Serotonergic and Noradrenergic Systems
Rueter et al.
J. Pharmacol. Exp. Ther. 1998;285:404-412.
ABSTRACT | FULL TEXT  

A 47-Year-Old Man With Chronic Depression
Goodwin
JAMA 1996;275:479-485.
ABSTRACT  

Pindolol, 5-Hydroxytryptamine, and Antidepressant Augmentation
Artigas
Arch Gen Psychiatry 1995;52:969-971.
ABSTRACT  

Biochemical Effects of Antidepressant Augmentation
Howland
Arch Gen Psychiatry 1995;52:156-156.
ABSTRACT  

Venlafaxine: the yin and yang of antidepressants?
Nutt
J Psychopharmacol 1995;9:205-206.
 

Combination Antidepressant Therapy in Primary Care
King et al.
Arch Fam Med 1994;3:1088-1092.
ABSTRACT  

Fluoxetine-Nortriptyline Therapy of Treatment-Resistant Major Depression in a Geriatric Patient
Rothschild
J Geriatr Psychiatry Neurol 1994;7:137-138.
ABSTRACT  

The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants
Anderson and Tomenson
J Psychopharmacol 1994;8:238-249.
ABSTRACT  

Progress in Psychiatry- First of Two Parts
Michels and Marzuk
NEJM 1993;329:552-560.
FULL TEXT  

Fluoxetine Inhibits Desipramine Metabolism
Wilens et al.
Arch Gen Psychiatry 1992;49:752-752.
ABSTRACT